BRD3308 is primarily used in biochemical and pharmacological research as a selective inhibitor of BET (bromodomain and extra-terminal) proteins, particularly targeting the BRD9 and BRD7 bromodomains. It serves as a valuable tool compound for studying chromatin regulation and gene expression in cellular models. Due to its specificity, BRD3308 helps researchers dissect the roles of individual BET family members in processes such as inflammation, cancer progression, and immune response. It has been employed in studies exploring epigenetic therapies, especially in oncology, where modulation of bromodomain-containing proteins can influence tumor growth and survival. Its application supports the development of targeted epigenetic drugs with improved selectivity and reduced off-target effects.